Eculizumab
| Eculizumab | |
|---|---|
| Term | Eculizumab |
| Short definition | eculizumab (ek-yoo-LIH-zoo-mab) A drug used to stop the destruction of red blood cells in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH ) to prevent. It is also used to treat another rare condition called atypical urea haemolytic syndrome (aHUS), in which blood clots form in small blood vessels. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
eculizumab - (pronounced) (ek-yoo-LIH-zoo-mab) A drug used to stop the destruction of red blood cells in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH ) to prevent. It is also used to treat another rare condition called atypical urea haemolytic syndrome (aHUS), in which blood clots form in small blood vessels. Eculizumab attaches to an immune system protein called C5. This helps prevent the breakdown of red blood cells and prevent blood clots from forming. Eculizumab is a type of monoclonal antibody. Also called Soliris
External links
- Medical encyclopedia article on Eculizumab
- Wikipedia's article - Eculizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski